Role of blue light cystoscopy to detect bladd …Change to Part B pay draws specialty ire …
Urology TimesUrologyBladder cancer
BLC scores well against WLC in recurrent bladder tumors
January 29, 2018 By Randy Dotinga
San Diego—Fluorescent blue light cystoscopy (BLC) improves 3-year recurrence-free survival (RFS) rates in patients with recurrent bladder tumors compared to white light cystoscopy (WLC), and researchers believe its use should be expanded.
“Although BLC has been approved for index transurethral resection, its use can be extended for recurrent tumors as well,” said lead author Tracy M. Downs, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, in an interview with Urology Times.
According to Dr. Downs, “Transurethral resection of bladder tumor (TURBT) is the standard of care for the non-muscle invasive subtype. Yet there is concern over the ability of TURBT done with WLC to identify small papillary tumors and flat carcinoma in situ lesions. The recurrence rate at 5 years after TURBT tumor with WLC is reported to be as high as 70%.”